Category Archives: Indian Patent Law

Chennai Patent Office revokes Pfizer’s second patent on Detrol

Source: Pharmabiz 24 Dec 2013 In yet another blow to the multinational drug companies in patent cases in India, the Chennai Patent Office has revoked Pfizer’s patent on Detrol, a drug used to manage overactive bladder symptoms. The patent on … Continue reading

Posted in Indian Patent Law, patent evergreening, Patent Opposition | Leave a comment

EU keen on concluding FTA talks with India

Source: Business Line Richard Bruton, Minister for Enterprise, Jobs and Innovation, Ireland NEW DELHI, NOV 19: The European Union (EU) is keen on concluding the long-pending negotiations for the Free Trade Pact with India by next year, Ireland Minister for … Continue reading

Posted in access to medicines, Biologics, EU-India FTA, Indian Patent Law, IP Rights, IPR Enforcement, patent, Right to Health | Tagged , , , , , | Leave a comment

How drug companies price patients out of survival

Source: Salon As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another health care battle rages in village clinics and corporate boardrooms. Behind the seductive commercials for breakthrough treatments, multinational brands … Continue reading

Posted in access to medicines, Compulsory Licensing, data exclusivity, EU-India FTA, FTAs, Generic drug, Government Use License, HIV/Aids, Indian Patent Law, IP Rights, IPR Enforcement, Medicine Patent Pool, NAFTA, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TB, Trans-Pacific Partnership Agreement, TRIPS, TRIPS flexibilities, WHO, WTO | Tagged , | Leave a comment

US pharma firms lobby to protect patents in India

Source: Business Line Pfizer, Mylan, Merck meet DIPP officials to protest against compulsory licences NEW DELHI, OCT. 23 US pharma majors are putting pressure on the Government to stop issuing permits to domestic companies for making low-priced copies of patented … Continue reading

Posted in access to medicines, FDI, Indian Patent Law, IP Rights, IPR Enforcement, patent, Right to Health | Tagged , | Leave a comment

News just in: Compulsory License application for Dasatinib rejected by Indian Patent Office

Indian Patent Office rejected the Compulsory License application filed by the Indian generic company- BDR Pharmaceuticals (filed in March 2013) for cancer drug Dasatinib used for the treatment of chronic myeloid leukemia. The application was rejected on procedural grounds. The … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, Injunctions | Leave a comment

SURPRISE! BIG PHARMA DON’T WANT DEVELOPING COUNTRIES HAVING ACCESS TO CHEAP MEDICINE

Source: http://www.vice.com Compared to a number of other nations, India has done an incredible job of keeping medicine cheap enough that its citizens can afford to buy whatever it is that they need. Most importantly, it avoids handing out patents … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS flexibilities | Leave a comment

India patent office holding consultations on Requirement of Disclosure of INN (generic name of the drug) in Patent Applications

India – Patent Office considering the requirement of disclosure of INN (generic name of the drug) in patent applications -holds regional consultations and invites submissions All four patent offices of India (Delhi, Mumbai, Chennai and Kolkata) are holding consultations on … Continue reading

Posted in Indian Patent Law, International Non-Proprietary Names, TRIPS | 1 Comment

TPPA goes into overdrive and underground

Source: Scoop Moves to get the Trans-Pacific Partnership Agreement (TPPA) to the point of sign-off by the end of the year went into overdrive at the round just ended in Brunei, according to Professor Jane Kelsey who was present as … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, Indian Patent Law, Investment treaties, investor state dispute, IP Rights, patent, Right to Health, WHO, WTO | Leave a comment

Roche relinquishes Trastuzumab patent in India:Campaign urges fast track approval for bio-similars

16 August 2013, New Delhi: Swiss pharma major Roche has just announced that it is relinquishing the patent for its breast-cancer drug Trastuzumab (Herceptin) in India. The announcement comes in the face of mounting challenges – from both civil society … Continue reading

Posted in access to medicines, Campaign for Affordable Trastuzumab, Clinical Trials, Compulsory Licensing, Drug Pricing, Generic drug, Indian Patent Law, IP Rights, patent, patent evergreening, Patent examination system | Leave a comment

TAC & MSF Memorandum to DTI to urgently Fix the Patent Laws

This is a memorandum dated 7th August delivered to representatives from the Department for Trade and Industry, including Minister Rob Davies, ahead of a workshop in coordination with the WTO, WHO, WIPO calling on the DTI to urgently “Fix the Patent … Continue reading

Posted in access to medicines, Compulsory Licensing, Generic drug, Indian Patent Law, IP Rights, patent, Patent examination system, Patent Opposition | Leave a comment